Key Points for Decision Makers {#FPar1}
==============================

Real-world evidence of disease prevalence is important for estimating the burden of disease, cost of illness and budget impact of new health technologies.The Danish civil registration number provides a unique opportunity to link different types of register data for an individual patient, thus providing the best possible information on the actual treatment of chronic diseases.Nationwide register-based prevalence statistics for 199 chronic diseases show, for most disease areas, a higher current treatment level than that expected from epidemiological research. In 2013, almost two-thirds of the entire Danish population aged 16 years or above either had a hospital diagnosis or had been in medical treatment for one or more chronic condition.

Introduction {#Sec1}
============

Worldwide, the financial pressures on healthcare providers are increasing. To control the rising cost of healthcare, decision makers need access to real-world evidence of current treatment patterns \[[@CR1], [@CR2]\]. Real-world evidence of disease prevalence is important for estimating the burden of disease, cost of illness, and budget impact of new health technologies \[[@CR3], [@CR4]\]. In addition, it is important to obtain unbiased, independent documentation of disease burden, as there may be concerns with the cost-of-illness studies funded by companies \[[@CR5]\].

The burden of chronic diseases is increasing rapidly in most countries. In Denmark, approximately 30--50% of the adult population have one or more chronic condition or long-standing illness \[[@CR6]--[@CR10]\]. Moreover, the burdens of chronic conditions are increasing \[[@CR11]--[@CR20]\]. The numbers and expenditure are growing along with an ageing population, and up to 80% of total healthcare costs can be attributed to chronic conditions \[[@CR21]--[@CR24]\]. Thus, the need for reliable and affordable estimates of the prevalence and disease burden of chronic conditions to guide decision-making in healthcare is increasing \[[@CR24]--[@CR26]\].

There are different ways to measure the prevalence of chronic conditions, varying from community-based health surveys and screening investigations to register-based studies. The choice of definitions and methods naturally affects which patients are included and hence the prevalence \[[@CR27], [@CR28]\].

The Scandinavian countries have an established tradition of documenting the diseases and hospital treatments of the entire population in registers; however, the registers have primarily been used to study individual conditions rather than to assess the total burden of chronic conditions \[[@CR7], [@CR24], [@CR26], [@CR29]--[@CR34]\], or to forecast drug spending to help with decision-making \[[@CR35], [@CR36]\].

The aim of the present study was to estimate the national prevalence rates and to summarise the characteristics of 199 chronic conditions using the complete Danish population aged 16 and above. To the best of the authors' knowledge, the current study is the most comprehensive, independent register-based attempt to estimate the full-population prevalence-based disease burden of chronic diseases.

Methods {#Sec2}
=======

Study Population {#Sec3}
----------------

The nationwide study population and cohort consisted of 4,555,439 Danish residents who were alive and aged 16 years or above on 1 January 2013, of which 49.2% were men.

The Registers {#Sec4}
-------------

In Scandinavian countries, general practitioners (GPs) and hospitals have a long-standing tradition of reporting diseases, treatments, medications and other treatment-related information. This is done at the micro level for national health registers. Register data are collected mostly for public administration such as claims and management, surveillance and control functions \[[@CR37]\]. The comprehensiveness, scope and population completeness are unique to Denmark and other Scandinavian countries, enabling individual linkage across registers by means of the individual personal identification number assigned to each person \[[@CR38]\]. The main register used was the Danish National Patient Register (NPR) \[[@CR39]\], including the Danish Psychiatric Central Research Register \[[@CR40]\], containing treating-physician-reported International Statistical Classification of Diseases, 10th Revision (ICD-10) hospital diagnoses. Moreover, to ensure the inclusion of patients not treated in hospitals, the National Health Service Register (NHSR) \[[@CR41]\] and National Prescription Registry (TNPR) \[[@CR42]\] were included in the study, since the NPR did not include diagnosis data from private specialist doctors or GPs. The NHSR contains data collected primarily for administrative purposes from health contractors in primary healthcare. It includes information about citizens, providers and health services, but minimal clinical information. Furthermore, the TNPR, comprising all prescribed and distributed medicines outside hospitals, was included to ensure the best possible identification of conditions and the representativeness thereof by clinical recommendation. All registers had a unique civil registration number for each person; furthermore, birth date, gender and other information were derived from the Danish Civil Registration System \[[@CR43]\]. The registers used are described in more detail in other studies \[[@CR44], [@CR45]\]. Table [1](#Tab1){ref-type="table"} summarises the details of the registers used.Table 1The registers used and characteristics of the selected population in summaryRegistryYears of registry usePopulationContainsThe National Patient Register \[[@CR39]\]1994--2012All somatic hospital-treated in/outpatients. Primary, secondary and additional diagnosis for patients aged 16 years or aboveICD-10 diagnosis codes for all public and private hospital-treated patients for every contact and treatment for the entire population as well as a civil registration number. Furthermore, data from all hospital treatments/procedures/operations for all hospital-treated patients as well as a civil registration numberThe Danish Psychiatric Central Research Register \[[@CR40]\]1995--2012All psychiatric hospital-treated in/outpatients. Primary, secondary and additional diagnosis for patients aged 16 years or aboveICD-10 diagnosis codes for all public hospital-treated patients for every contact and treatment for the entire population as well as a civil registration number. No private psychiatric hospital existsThe National Health Service Register \[[@CR41]\]2000--2012All patients in primary care aged 16 years or aboveAll GP services for whole population and every consultation based on civil registration number. The register does not contain information on diagnosis, but many services are disease-specific and can thus be used for identifying chronic conditionsThe Danish National Prescription Registry \[[@CR42]\]1995--2012All patients in primary care with a prescription who are aged 16 years or aboveAll Danish medicine prescriptions sold for the entire population using 6-digit ATC codes as well as a civil registration numberThe Danish Civil Registration System \[[@CR43]\]2013Whole population aged 16 years or above resident in Denmark on 1 January 2014Data regarding birth date, age, gender, etc. for the entire population as well as a civil registration number*ATC* Anatomical Therapeutic Chemical Classification System, *GP* general practitioner, *ICD*-*10* International Statistical Classification of Diseases, 10th Revision

The Definition of a 'Chronic Condition', Clinical Ratification and Review {#Sec5}
-------------------------------------------------------------------------

A thorough description of the distinct phases and methods used are provided elsewhere \[[@CR44]--[@CR46]\]. In short, a 'chronic condition' was defined in line with previous studies, i.e. the 'condition had lasted or was expected to last twelve or more months and resulted in functional limitations and/or the need for functional limitations and/or the need for ongoing medical care' \[[@CR47]--[@CR49]\]. An expert panel consisting of professors, medical specialists and other experts from Aalborg University, the Clinical Institute of Aalborg University at Aalborg University Hospital, the Department of Clinical Epidemiology at Aarhus University Hospital, and others was consulted using the Delphi method in order to identify which of the approximately 22,000 ICD-10 codes and conditions could be considered 'chronic' based on the definition \[[@CR44]\]. The ICD-10 codes were aggregated to 199 conditions, yet several conditions included subgroups of ICD-10 codes; thus, some consequently contained multiple conditions within the same disease area. Subsequently, all ICD-10 conditions considered chronic by definition were included in the study in pursuit of comprising the full-population burden of chronic conditions. Consequently, the 199 conditions consisted of several ICD-10 codes and thus groups of illnesses.

Data Collection: The Basis of the Data Algorithms {#Sec6}
-------------------------------------------------

Since many chronic conditions last longer than the defined 12 months, but do not last for a lifetime, the varying 'chronicity' of conditions was divided into four groups of severity \[[@CR44]\]:Category I: stationary to progressive chronic conditions (no time limit equals inclusion time going back from the time of interest for as long as valid data were available. In the current study, this starting point was defined by the introduction of the ICD-10 diagnosis coding in Denmark, in 1994).Category II: stationary to diminishing chronic conditions (10 years from register inclusion time to the time of interest).Category III: diminishing chronic conditions (5 years from register inclusion time to the time of interest).Category IV: borderline chronic conditions (2 years from register inclusion time to the time of interest).

The above four categories were designed to include the different chronic conditions when registers covered several years and still have the best possible clinical certainty that the conditions were still existing at the fixed time point of 1 January 2013. All 199 chronic conditions were divided into one of the four categories by medical specialists and experts. An algorithm was created for data collection based on the four categories, as seen in Fig. [1](#Fig1){ref-type="fig"} for all 199 conditions and coherent ICD-10 codes. However, 35 of the 199 chronic conditions were not considered by experts to be properly representative using solely NPR diagnosis data. Thus, they created more complex algorithms using several registers besides diagnosis data, ranging from medicine and hospital treatments to GP services. For example, medicine and coherent indication codes were used to identify people with depression without a hospital diagnosis, and only when the indication codes identified the medicine used for depression, and not others such as pain treatment, etc. The same applied to GP services indicating, for example, diabetes or chronic obstructive lung disease (COPD) treatment, etc., where no hospital diagnosis was found. The details of all 199 unique definitions, their categorisation into one of the four categories and algorithms for replication can be found elsewhere \[[@CR44], [@CR45]\].Fig. 1The four categories of chronicity and the inclusion time periods

Statistical Analysis {#Sec7}
--------------------

Prevalence estimates were calculated in both per cent and per 1000 subjects; the proportion was calculated as the number of conditions identified divided by the total number of residents aged 16 years or above alive on 1 January 2013 (*n *=4,555,439) multiplied by either 100 or 1000. Thus, prevalence was calculated from a specific point in time, based on the above inclusion time periods back in time for each condition. See Fig. [1](#Fig1){ref-type="fig"} or further details in the literature \[[@CR44]\].

The prevalence proportions for all conditions were stratified and presented by age and sex for use by, for example, local authorities, health planners and national researchers.

Direct standardisation of age, gender and education based on the national average (i.e. using Denmark as the standard/reference population for age, gender and education) \[[@CR50]\] was applied to illustrate differences free of basic socio-economic effects (presented in brackets in Tables 2 and 3 and the electronic supplementary material). The gender and age (10-year intervals) variables were obtained from the Danish Civil Registration System \[[@CR43]\], and the educational variables were obtained from the Population Education Register using Danish Education Nomenclature (DUN) classification \[[@CR51]\].

Finally, tables were stratified geographically in the five national regions, and the mean age and standard deviation (SD) for each condition were calculated, but due to size and relevance for the international reader, geographical regions, mean age and SDs are presented in the electronic supplementary material.

All data management and data analysis were performed in SAS 9.4 (from Statistics Denmark's research servers).

Results {#Sec8}
=======

The Prevalence Rates {#Sec9}
--------------------

The population's full burden of chronic disease, with all the chronic conditions summarised, was 65.6% (see Table [2](#Tab2){ref-type="table"} or Table [3](#Tab3){ref-type="table"}). The ten most prevalent conditions were hypertension (23.3%), respiratory allergy (18.5%), disorders of lipoprotein metabolism (14.3%), depression (10.0%), bronchitis (9.2%), asthma (7.9%), type 2 diabetes (5.3%), COPD (4.7%), osteoarthritis of the knee (3.9%) and osteoporosis (3.5%)/ulcer (3.5%); see the overview of conditions solely by overall disease groups in Table [2](#Tab2){ref-type="table"} and all 199 conditions in Table [3](#Tab3){ref-type="table"}.Table 2Overview of disease prevalence in Denmark: number of patients, prevalence rate (per 1000), age and gender (per cent within gender) of *disease groups* of conditions and chosen medicine for Denmark at 1 January 2013Name of conditionICD-10 code/definitionNumber and prevalenceDenmarkMenAge 16--44 (per 1000)Age 45--74 (per 1000)Age 75 + (per 1000)*N*Per 1000 (standardised)Per centB---Viral hepatitis and human immunodeficiency virus (HIV) diseaseB18, B20--B2488131.9(2.0)65.31.82.40.3C---Malignant neoplasmsC00--C99; D32--D33; D35.2--D35.4; D42--D44229,33150.3(50.4)43.310.269.4155.8D---In situ and benign neoplasms, and neoplasms of uncertain or unknown behaviour and diseases of the blood and blood-forming organs and certain disorders involving the immune mechanismD00--D09; D55--D59; D60--D67; D80--D89116,56025.6(25.7)36.313.227.380.1E---Endocrine, nutritional and metabolic diseasesE00--E14; E20--E29; E31--35; E70--E78; E84--E85; E88--E89877,433192.6(192.7)45.643.5279.6501.4G---Diseases of the nervous systemG00--G14; G20--G32; G35--G37; G40--47; G50--64; G70--73; G80--G83; G90--G99561,054123.2(123.5)40.170.6162.2188.6H---Diseases of the eye and adnexa and diseases of the ear and mastoid processH02--H06; H17--H18; H25--H28; H31--H32; H34--H36; H40--55; H57; H80, H810; H93, H90--H93448,17698.4(98.6)47.525.6112.6394.4I---Diseases of the circulatory systemI05--I06; I10--28; I30--33; I36--141; I44--I52; I60--I88; I90--I94; I96--I991,254,427275.4(275.5)45.373.3381.5753.9J---Diseases of the respiratory systemJ30.1; J40--J47; J60--J84; J95, J97--J991,210,598265.7(266.3)42.1209.3298.8381.9K---Diseases of the digestive systemK25--K27; K40, K43, K50--52; K58--K59; K71--K77; K86--K87329,33772.3(72.6)44.741.386.3157.4L---Diseases of the skin and subcutaneous tissueL4065,46914.4(14.5)47.87.919.321.7M---Diseases of the musculoskeletal system and connective tissueM01--M25; M30--M36; M40--M54; M60.1--M991,032,808226.7(227.1)42.2113.2291.2470.5N---Diseases of the genitourinary systemN1820,1624.4(4.5)59.41.04.820.0Q---Congenital malformations, deformations and chromosomal abnormalitiesQ00--Q56; Q60--Q99124,89827.4(27.5)41.733.923.216.2F---Mental and behavioural disordersF00--99683,194150.0(150.7)41.0135.2150.2223.7**Having one or more chronic condition2,989,441656.2(657.2)45.5480.5771.5953.9Mean number of chronic conditions (std. dev)2.2 (2.8)**----**2.0 (2.6)1.1 (1.6)2.7 (2.8)5.3 (3.6)** Depression medicine^c,^\*\*ATC: N06A529,918116.3(116.7)36.388.7126.9201.9 Antipsychotic medicine^c,^\*\*ATC: N05A138,62530.4(30.6)45.726.131.944.8 Indication prescribed anxiety medicine^c,^\*\*All prescriptions with either indication code 163 (for anxiety) or 371 (for anxiety, addictive)102,56822.5(22.6)34.519.923.730.1 Heart failure medication^c,^\*\*ATC: C01AA05, C03, C07 or C09A with indication code 430 (for heart failure)74681.6(1.7)64.60.12.07.5 Ischaemic heart medication^c,^\*\*ATC: C01A, C01B, C01D, C01E129,48428.4(28.5)51.81.432.0147.3**All of the five types of medicine above688,006151.0(151.6)40.4100.2166.1331.1**Standardised rates or standard devitions in bracketsSee table with 10-year age intervals in Supplementary Material 2 in the electronic supplementary matertialConditions marked 'A' overlap with other conditions and are thus not counted twice \[[@CR44]\]*ATC* Anatomical Therapeutic Chemical Classification System, *ICD*-*10* International Statistical Classification of Diseases, 10th Revision^c^Complex defined conditions; see reference for further details \[[@CR44]\]\*\*Two-year prevalenceTable 3Disease prevalence of 199 chronic conditions: number of patients treated, prevalence rate (per 1000), age and gender (per cent within gender) of all conditions and chosen medicine for Denmark at 1 January 2013No.Name of conditionICD-10 code/definitionNumber and prevalenceDenmarkMenAge 16--44 (per 1000)Age 45--74 (per 1000)Age 75+ (per 1000)*N*Per 1000 (standardised)Per cent**B---Viral hepatitis and human immunodeficiency virus \[HIV\] diseaseB18, B20--B2488131.9(2.0)65.31.82.40.3**1Chronic viral hepatitisB1845841.0(1.0)60.11.01.20.12Human immunodeficiency virus \[HIV\] diseaseB20--2442290.9(0.9)71.00.81.20.1**C---Malignant neoplasmsC00--C99; D32--D33; D35.2--D35.4; D42--D44229,33150.3(50.4)43.310.269.4155.8**3Malignant neoplasms of other and unspecified localizationsC00--C14; C30--C33; C37--C42; C45--C49; C69; C73--74; C754--C75920,5574.5(4.6)53.51.36.610.14Malignant neoplasms of digestive organsC15--C17; C22--C2648391.1(1.1)59.50.11.63.45Malignant neoplasm of colonC1818,8264.1(4.1)47.00.24.920.36Malignant neoplasms of rectosigmoid junction, rectum, anus and anal canalC19--C2110,6802.3(2.3)55.40.13.29.57Malignant neoplasm of bronchus and lungC3414,7623.2(3.3)49.40.24.810.68Malignant melanoma of skinC4319,6364.3(4.3)42.62.05.79.09Other malignant neoplasms of skinC4415,5973.4(3.4)51.20.33.916.710Malignant neoplasm of breastC5050,68711.1(11.1)0.71.017.629.511Malignant neoplasms of female genital organsC51--C52; C56--C5872451.6(1.6)--0.32.43.912Malignant neoplasm of cervix uteri, corpus uteri and part unspecifiedC53--C5511,6082.5(2.5)0.00.73.57.113Malignant tumour of male genitaliaC60, C62--C6351941.1(1.1)99.91.21.20.714Malignant neoplasm of prostateC6126,6975.9(5.9)100.00.07.527.015Malignant neoplasms of urinary tractC64--C6810,3192.3(2.3)71.20.12.99.916Brain cancer^c^C71, C75.1--C75.3, D33.0--D33.2, D35.2--D35.4, D43.0--D43.2, D44.3--D44.5 (brain). C70, D32, D42 (brain membrane). C72, D33.3--D33.9, D43.3--D43.9 (cranial nerve, spinal cord)15,3103.4(3.4)52.91.44.76.217Malignant neoplasms of ill-defined, secondary and unspecified sites, and of independent (primary) multiple sitesC76--C80, C9725,6195.6(5.6)43.01.28.414.018Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissueC81--C9619,7124.3(4.3)54.41.55.612.4**D---In situ and benign neoplasms, and neoplasms of uncertain or unknown behaviour and diseases of the blood and blood-forming organs and certain disorders involving the immune mechanismD00--D09; D55--D59; D60--D67; D80--D89116,56025.6(25.7)36.313.227.380.1**19In situ neoplasmsD00--D0919,8104.3(4.4)20.02.55.57.920Haemolytic anaemiasD55--D5930550.7(0.7)33.70.70.61.221Aplastic and other anaemiasD60--D6314,9183.3(3.3)40.20.93.315.022Other anaemiasD6446,61310.2(10.3)38.72.39.753.123Coagulation defects, purpura and other haemorrhagic conditionsD65--D6925,3765.6(5.6)37.45.25.77.124Other diseases of blood and blood-forming organsD70--D7788962.0(2.0)43.51.02.63.625Certain disorders involving the immune mechanismD80--D8976601.7(1.7)50.81.42.01.3**E---Endocrine, nutritional and metabolic diseasesE00--E14; E20--E29; E31--35; E70--E78; E84--E85; E88--E89877,433192.6(192.7)45.643.5279.6501.4**26Diseases of the thyroid^c^E00--E04, E06, E07131,90829.0(29.0)15.911.339.166.227Thyrotoxicosis^c^E0541,3749.1(9.0)18.33.810.826.728Diabetes type 1^c^E1023,0625.1(5.1)57.94.95.63.529Diabetes type 2^c^E11242,17753.2(53.3)53.08.577.9152.130Diabetes others^c^E12--E1411170.2(0.2)48.60.20.30.531Disorders of other endocrine glandsE20--E35, except E3028,6506.3(6.4)28.66.55.68.932Metabolic disordersE70--E77; E79--E83; E85, E88--E89;23,6905.2(5.2)36.63.76.18.233Disturbances in lipoprotein circulation and other lipids^c^E78652,242143.2(143.1)51.111.8221.2408.134Cystic fibrosis^c^E849470.2(0.2)41.90.30.10.1**G---Diseases of the nervous systemG00--G14; G20--G32; G35--G37; G40--47; G50--64; G70--73; G80--G83; G90--G99561,054123.2(123.5)40.170.6162.2188.6**35Inflammatory diseases of the central nervous systemG00--G0976421.7(1.7)50.11.32.02.236Systemic atrophies primarily affecting the central nervous system and other degenerative diseasesG10--G14, G30--G3210,4012.3(2.3)46.80.42.212.137Parkinson's disease^c^G20, G21, G22, F02.357,58312.6(12.6)43.74.116.337.338Extrapyramidal and movement disordersG23--G2610,8372.4(2.4)41.81.12.96.439SclerosisG3513,2842.9(2.9)30.61.94.21.540Demyelinating diseases of the central nervous systemG36--G3745711.0(1.0)34.70.91.30.441Epilepsy^c^G40--G4161,69513.5(13.6)48.29.716.020.342Migraine^c^G43149,86632.9(33.0)18.624.944.115.643Other headache syndromesG4416,4693.6(3.6)35.94.03.61.844Transient cerebral ischaemic attacks and related syndromes and vascular syndromes of brain in cerebrovascular diseasesG45--G4643,9779.7(9.7)53.51.112.737.645Sleep disordersG4736,8068.1(8.1)73.54.112.65.046Disorders of trigeminal nerve and facial nerve disordersG50--G5121,4884.7(4.7)43.02.86.07.447Disorders of other cranial nerves, cranial nerve disorders in diseases classified elsewhere, nerve root and plexus disorders and nerve root and plexus compressions in diseases classified elsewhereG52--G5512,4292.7(2.7)48.91.34.03.648Mononeuropathies of upper limbG56122,39526.9(26.9)37.212.639.136.549Mononeuropathies of lower limb, other mononeuropathies and mononeuropathy in diseases classified elsewhereG57--G5918,6274.1(4.1)43.81.96.15.050Polyneuropathies and other disorders of the peripheral nervous systemG60--G6430,2896.6(6.7)56.41.79.318.251Diseases of myoneural junction and muscleG70--G7357581.3(1.3)47.70.91.51.652Cerebral palsy and other paralytic syndromesG80--G8314,4103.2(3.2)53.92.93.53.253Other disorders of the nervous systemG90--G9944,3949.7(9.8)46.45.912.117.0**H---Diseases of the eye and adnexa and diseases of the ear and mastoid processH02--H06; H17--H18; H25--H28; H31--H32; H34--H36; H40--55; H57; H80, H810; H93, H90--H93448,17698.4(98.6)47.525.6112.6394.4**54Disorders of eyelid, lacrimal system and orbitH02--H0613,1912.9(2.9)37.30.94.07.555Corneal scars and opacitiesH1721730.5(0.5)58.10.20.51.356Other disorders of corneaH1894732.1(2.1)43.51.02.17.457Diseases of the eye lens (cataracts)H25--H2868,00914.9(15.1)40.50.515.684.858Disorders of the choroid and retinaH31--H3219000.4(0.4)48.30.20.51.159Retinal vascular occlusionsH3410,3582.3(2.3)50.80.22.611.460Other retinal disordersH3568,48515.0(15.1)40.21.613.093.761Retinal disorders in diseases classified elsewhereH3619,2794.2(4.3)58.71.76.17.462Glaucoma^c^H40--H4267,31014.8(14.9)43.51.216.276.463Disorders of the vitreous body and globeH43--H4575721.7(1.7)44.60.72.43.164Disorders of optic nerve and visual pathwaysH46--H4861841.4(1.4)39.01.21.61.465Disorders of ocular muscles, binocular movement, accommodation and refractionH49--H5218,2474.0(4.0)45.44.33.92.866Visual disturbancesH5322,2324.9(4.9)45.72.65.911.167Blindness and partial sightH5466141.5(1.5)44.40.61.55.668Nystagmus and other irregular eye movements and other disorders of eye and adnexaH55, H5711,1332.4(2.5)40.31.73.03.769OtosclerosisH8010,3602.3(2.3)35.70.83.15.470Ménière's disease^c^H81010,0032.2(2.2)43.00.43.07.371Other diseases of the inner earH8329,8656.6(6.3)91.80.69.024.572Conductive and sensorineural hearing lossH9043,2389.5(9.6)48.73.711.329.573Other hearing loss and other disorders of ear, not elsewhere classifiedH910, H912, H913, H918, H930, H932, H93383061.8(1.8)53.00.72.35.274Presbycusis (age-related hearing loss)H91180,65917.7(17.6)48.90.49.6147.475Hearing loss, unspecifiedH91987,80619.3(19.3)55.33.024.574.576TinnitusH93140,1248.8(8.7)58.42.513.417.577Other specified disorders of earH93820,5374.5(4.4)48.10.85.916.1**I---Diseases of the circulatory systemI05--I06; I10--28; I30--33;I36--141; I44--I52; I60--I88; I90--I94; I96--I991,254,427275.4(275.5)45.373.3381.5753.9**78Aortic and mitral valve disease^c^I05, I06, I34, I3530,1236.6(6.6)50.90.76.437.779Hypertensive diseases^c^I10--I151,060,046232.7(232.7)44.641.8330.8695.880Heart failure^c^I11.0, I13.0, I13.2, I42.0, I42.6, I42.7, I42.9, I50.0, I50.1, I50.937,5408.2(8.3)63.50.79.540.380AIschaemic heart diseasesI20--I25139,17330.6(30.7)60.22.641.8114.581Angina pectorisI2078,47617.2(17.3)58.41.625.753.082Acute myocardial infarction andsubsequent myocardial infarctionI21--I2236,6548.0(8.1)66.60.711.129.883AMI complex/otherI23--I2429690.7(0.7)61.30.10.92.384Chronic ischaemic heart diseaseI2584,59218.6(18.6)64.70.823.881.485Pulmonary heart disease and diseases of pulmonary circulationI26--I2815,3523.4(3.4)44.81.03.813.086Acute pericarditisI3055631.2(1.2)73.11.01.41.387Other forms of heart diseaseI31--I43, except I34--I35 and I428,1191.8(1.8)60.50.72.15.488Atrioventricular and left bundle branch blockI4414,6043.2(3.2)58.70.42.720.089Other conduction disordersI45--4611,8232.6(2.6)59.61.02.89.590Paroxysmal tachycardiaI4739,5108.7(8.7)48.13.311.023.991Atrial fibrillation and flutterI48112,34224.7(24.7)57.21.726.5132.092Other cardiac arrhythmiasI4934,4187.6(7.6)47.92.28.728.893Complications and ill-defined descriptions of heart disease and other heart disorders in diseases classified elsewhereI51--5273371.6(1.6)50.30.61.85.794StrokeI60, I61,I63--I64, Z501 (rehabilitation)72,60615.9(16.0)54.21.619.868.795Cerebrovascular diseasesI62, I65--I6817,3083.8(3.8)51.10.84.913.396Sequelae of cerebrovascular diseaseI6950,95211.2(11.2)52.50.812.755.997AtherosclerosisI7032,0647.0(7.0)53.60.48.334.298Aortic aneurysm and aortic dissectionI7110,2962.3(2.3)72.20.12.611.299Diseases of arteries, arterioles and capillariesI72, I74, I77--I7911,8302.6(2.6)45.61.03.46.2100Other peripheral vascular diseasesI7328,5086.3(6.3)54.80.78.324.4101Phlebitis, thrombosis of the portal vein and othersI80--I8237,3888.2(8.3)45.53.510.222.2102Varicose veins of lower extremitiesI8323,5305.2(5.2)30.63.26.86.6103Haemorrhoids^c^I8474,28516.3(16.3)40.114.517.519.0104Oesophageal varices (chronic), varicose veins of other sites, other disorders of veins, non-specific lymphadenitis, other non-infective disorders of lymphatic vessels and lymph nodes and other and unspecified disorders of the circulatory systemI85--I99, except I89 and I9515,1943.3(3.3)52.62.23.96.1**J---Diseases of the respiratory systemJ30.1; J40--J47; J60--J84; J95, J97--J991,210,598265.7(266.3)42.1209.3298.8381.9**105Respiratory allergy^c^J30, except J30.0841,685184.8(185.2)41.0154.0204.3240.3105AChronic lower respiratory diseases^c^J40--J43, J47418,12091.8(92.0)39.857.8112.8156.3106Bronchitis, not specified as acuteor chronic, simple andmucopurulent chronic bronchitisand unspecified chronic bronchitisJ40--J4212,7902.8(2.8)43.60.43.511.3107EmphysemaJ4355571.2(1.2)51.10.21.73.7108Chronic obstructive lung disease (COPD)^c^J44, J96, J13--J18216,18447.5(47.6)45.017.660.6131.4109Asthma, status asthmaticus^c^J45--J46361,12979.3(79.4)42.164.286.5118.4110BronchiectasisJ4743621.0(1.0)35.00.31.42.2111Other diseases of the respiratory systemJ60--J84; J95, J97--J9921,9934.8(4.9)52.51.56.214.6**K---Diseases of the digestive systemK25--K27; K40, K43, K50--52; K58--K59; K71--K77; K86--K87329,33772.3(72.6)44.741.386.3157.4**112Ulcers^c^K25--K27157,37934.5(34.8)43.215.342.491.9113Inguinal herniaK4025,0325.5(5.5)88.72.17.711.5114Ventral herniaK4379411.7(1.7)44.70.72.53.3115Crohn's dieaseK5018,9134.2(4.2)41.44.44.13.4116Ulcerative colitisK5129,5386.5(6.5)45.25.47.28.2117Other non-infective gastroenteritis and colitisK5220,8444.6(4.6)35.52.65.012.8118Irritable bowel syndrome (IBS)K5837,5938.3(8.3)29.97.59.08.4119Other functional intestinal disordersK5951,93311.4(11.5)37.06.511.834.1120Diseases of liver, biliary tract and pancreasK71--K77; K86--K8726,9565.9(6.0)48.62.48.88.5**L---Diseases of the skin and subcutaneous tissueL4065,46914.4(14.5)47.87.919.321.7**121Psoriasis^c^L4065,46914.4(14.5)47.87.919.321.7**M---Diseases of the musculoskeletal system and connective tissueM01--M25; M30--M36; M40--M54; M60.1--M991,032,808226.7(227.1)42.2113.2291.2470.5**122Infectious arthropathiesM01--M0394022.1(2.1)49.71.82.32.1122AInflammatory polyarthropathies and ankylosing spondylitis^c^M05--M14, M45165,94436.4(36.5)51.712.750.484.9123Rheumatoid arthritis^c^M05, M06, M07.1, M07.2, M07.3, M08, M0977,34517.0(17.0)34.28.123.130.5124Inflammatory polyarthropathies-- except rheumatoid arthritis^c^M074--M079, M10--M14, M45115,94525.5(25.5)58.37.935.463.3125Polyarthrosis \[arthrosis\]M1516,9353.7(3.7)20.80.25.412.6126Coxarthrosis \[arthrosis of hip\]M16104,11522.9(22.7)43.32.026.8108.1127Gonarthrosis \[arthrosis of knee\]M17178,81139.3(39.4)44.25.058.6113.5128Arthrosis of first carpometacarpal joint and other arthrosisM18--M1991,10120.0(20.1)41.74.231.043.4129Acquired deformities of fingers and toesM2055,73012.2(12.3)21.35.517.917.1130Other acquired deformities of limbsM2120,5844.5(4.5)34.92.75.86.9131Disorders of patella (knee cap)M2238,9998.6(8.6)38.013.75.00.6132Internal derangement of kneeM230, M231, M233, M235, M236, M23891922.0(2.0)55.62.81.50.4133Derangement of meniscus due to old tear or injuryM23236,3748.0(8.0)53.66.910.22.5134Internal derangement of knee, unspecifiedM23928,2066.2(6.2)50.06.96.32.3135Other specific joint derangementsM24, except M240--M24159231.3(1.3)57.21.90.90.5136Other joint disorders, not elsewhere classifiedM2512,0432.6(2.7)34.72.33.11.9137Systemic connective tissue disordersM30--M36, except M32,M3442,6319.4(9.4)24.74.210.032.3138Systemic lupus erythematosusM3233760.7(0.7)12.90.51.00.7139DermatopolymyositisM3311370.2(0.2)39.80.10.40.4140Systemic sclerosisM3416750.4(0.4)21.00.10.60.5141Kyphosis, lordosisM4041600.9(0.9)47.70.71.10.7142ScoliosisM4117,6863.9(3.9)31.95.02.74.3143Spinal osteochondrosisM4280341.8(1.8)63.41.42.21.0144Other deforming dorsopathiesM4323,7565.2(5.3)42.42.27.39.9145Other inflammatory spondylopathiesM4670861.6(1.6)45.51.11.92.0146SpondylosisM4761,99913.6(13.6)45.92.421.231.4147Other spondylopathies and spondylopathies in diseases classified elsewhereM48, M4950,80511.2(11.2)44.81.114.743.7148Cervical disc disordersM5011,4762.5(2.5)46.41.53.81.2149Other intervertebral disc disordersM5140,1618.8(8.9)49.46.411.47.6150Other dorsopathies, not elsewhere classifiedM5372461.6(1.6)40.91.41.91.2151DorsalgiaM5440,7809.0(9.0)42.97.310.011.9152Soft tissue disordersM60--M63, except M60.013,4222.9(3.0)28.63.22.82.4153Synovitis and tenosynovitisM6519,1044.2(4.2)37.53.15.43.8154Disorders of synovium and tendonM66--6819,6694.3(4.3)41.74.74.32.1155Soft tissue disorders related to use, overuse and pressureM7011,0902.4(2.4)42.41.63.03.4156Fibroblastic disordersM7243,6009.6(9.6)63.72.314.222.6157Shoulder lesionsM7558,11212.8(12.7)50.37.219.08.6158Enthesopathies of lower limb, excluding footM7611,2232.5(2.5)49.42.72.60.9159Other enthesopathiesM7710,5002.3(2.3)40.41.92.91.0160Rheumatism, unspecifiedM79068521.5(1.5)13.70.72.31.2161MyalgiaM79110,1682.2(2.2)36.81.42.93.0162Other soft tissue disorders, not elsewhere classifiedM792-- M794; M798--M79979391.7(1.7)36.91.52.01.7163Other soft tissue disorders, not elsewhere classified: pain in limbM79622,2014.9(4.9)41.53.95.56.7164FibromyalgiaM79733990.7(0.7)4.50.61.00.3165Osteoporosis^c^M80--M81158,81334.9(34.8)15.30.743.5163.6166Osteoporosis in diseases classified elsewhereM8210070.2(0.2)35.20.10.30.7167Adult osteomalacia and other disorders of bone density and structureM83, M85, except M83343,2719.5(9.5)19.21.914.422.7168Disorders of continuity of boneM8418650.4(0.4)51.60.30.50.5169Other osteopathiesM86--M9024,2515.3(5.3)38.42.27.012.4170Other disorders of the musculoskeletal system and connective tissueM95--M9930,0386.6(6.6)52.15.47.48.2**N---Diseases of the genitourinary systemN1820,1624.4(4.5)59.41.04.820.0**171Chronic renal failure (CRF)^c^N1820,1624.4(4.5)59.41.04.820.0**Q---Congenital malformations, deformations and chromosomal abnormalitiesQ00--Q56; Q60--Q99124,89827.4(27.5)41.733.923.216.2**172Congenital malformations: of the nervous, circulatory and respiratory systems, cleft palate and cleft lip, urinary tract, bones and muscles, other and chromosomal abnormalities not elsewhere classifiedQ00--Q07; Q20--Q37; Q60--Q9985,53418.8(18.9)37.823.715.69.8173Congenital malformations of eye, ear, face and neckQ10--Q1819,6894.3(4.3)38.86.23.01.8174Other congenital malformations of the digestive systemQ38--Q4564811.4(1.4)41.81.01.62.9175Congenital malformations of the sexual organsQ50--Q5616,1923.6(3.6)64.34.13.31.9**F---Mental and behavioural disordersF00--99683,194150.0(150.7)41.0135.2150.2223.7**176Dementia^c^F00, G30, F01, F02.0, F03.9, G31.8B, G31.8E, G31.9, G31.0B36,8038.1(8.1)36.30.03.771.7177Organic, including symptomatic, mental disordersF04--F0926,4305.8(5.9)48.82.55.822.6178Mental and behavioural disorders due to use of alcoholF1059,14313.0(13.2)67.09.417.57.9179Mental and behavioural disorders due to psychoactive substance useF11--F1953,66911.8(11.9)54.213.311.27.2180Schizophrenia^c^F2029,4226.5(6.5)58.27.16.62.2181Schizotypal and delusional disordersF21--F2939,6948.7(8.8)50.39.28.76.2182Bipolar affective disorder^c^F30--F3122,6695.0(5.0)40.63.66.25.7183Depression^c^F32, F33, F34.1, F06.32454,93399.9(100.2)35.579.1107.5165.8184Mood (affective) disordersF340, F348--F349, F38--F3968871.5(1.5)35.91.31.61.7185Phobic anxiety disordersF4014,3243.1(3.2)33.45.01.90.3186Other anxiety disordersF4138,0798.4(8.4)32.610.07.35.3187Obsessive compulsive disorder (OCD)^c^F4210,0622.2(2.2)36.73.81.00.5188Post-traumatic stress disorderF43116,0553.5(3.6)48.63.93.80.4189Reactions to severe stress and adjustment disordersF432--F43961,70113.5(13.7)39.118.610.44.4190Dissociative (conversion) disorders, somatoform disorders and other neurotic disordersF44, F45, F4821,4204.7(4.7)31.74.65.23.1191Eating disordersF5077511.7(1.7)5.23.50.30.1192Behavioural syndromes associated with physiological disturbances and physical factorsF51--F5961631.4(1.3)46.31.91.00.3193Emotionally unstable personality disorderF60321,8484.8(4.9)21.27.72.80.2194Specific personality disordersF602, F604--F60950,41511.1(11.2)39.314.49.42.7195Disorders of adult personality and behaviourF61--F6917,5333.8(3.9)44.35.03.30.7196Mental retardationF70--F7913,8223.0(3.1)53.93.82.61.2197Disorders of psychological developmentF80--F8999112.2(2.2)65.44.10.60.3198Hyperkinetic disorders (ADHD)^c^F9042,9089.4(9.5)60.617.13.51.0199Behavioural and emotional disorders with onset usually occurring in childhood and adolescenceF91--F9939,6028.7(8.8)48.311.86.63.7**Having one or more chronic conditions2,989,441656.2(657.2)45.5480.5771.5953.9**Standardised rates in bracketsSee table with 10-year age intervals in Supplementary Material 2 in the electronic supplementary materialConditions marked 'A', overlap with other conditions and are thus not counted twice \[[@CR44]\]*ICD*-*10* International Statistical Classification of Diseases, 10th Revision^c^ Complex defined conditions; see reference for further details \[[@CR44]\]\*\* 2-year prevalence

In general, prevalence naturally increases with increasing age across most conditions (see also Supplementary Material 2 and 6 with 10-year age intervals). Moreover, patients are relatively older within cancers and endocrine, nutritional and metabolic diseases and diseases of the circulatory system, the eye and adnexa, the ear and mastoid process, and the musculoskeletal system and connective tissue compared to within other conditions. A relatively younger patient population is seen within diseases of the respiratory system (especially allergies and asthma) and mental- and behavioural disorders. Mental disorders actually show a decrease in prevalence in later life. The conditions with the youngest population are, for example, seen within human immunodeficiency virus (HIV) and hepatitis.

Gender differences are seen across conditions, where women are overrepresented within most conditions---except, for example, heart failure and ischaemic heart diseases, stroke, some cancers, diabetes, disturbances in lipoprotein circulation and other lipids, inguinal hernia, hearing loss such as tinnitus, chronic renal failure, sleep disorders, schizophrenia, attention deficit/hyperactivity disorder (ADHD), mental and behavioural disorders due to the use of alcohol, and others. Coherently, women are treated more often than men with medication, except for ischaemic heart medications.

Some further characteristics and differences between conditions are seen and described in Supplementary Material 1--6. This includes geographic regional tables, further age characteristics with mean age and SD, more age intervals, further comments on common selected conditions and regional differences, etc.

Discussion {#Sec10}
==========

Based on the present findings, almost two-thirds of the entire Danish population aged 16 years or above have one or more chronic condition. Seen in the context of previous studies, this is around 10--20 percentage points higher than several other Danish studies \[[@CR6], [@CR7]\] as well as international studies \[[@CR27], [@CR28]\]. The overall estimates are also twice the official estimates of the Danish National Board of Health \[[@CR8]\]. However, both national and international comparisons are difficult due to differences in methodology and data possibilities, so estimates should be compared with caution. For example, some American studies report that about 50% of the US population has a chronic condition \[[@CR52], [@CR53]\], but reliable overall estimates are difficult to obtain as to why improvement has been recommended \[[@CR17]\]. Furthermore, as the US often has higher disease prevalence than the EU---often differing by 20--100% across different conditions \[[@CR54]\] ---the present study suggests that the US estimates might be even higher.

Strengths and Limitations {#Sec11}
-------------------------

The strength of this study is the detailed, full nationwide register-based collection and categorisation of all data on actual chronic conditions and treatments for Danes in public and private healthcare. Several limitations exist, however, one being the obvious fact that being treated for a chronic condition is not necessarily the same as being truly ill. There may be cases of defensive medicine or patients being treated on suspicion of a chronic disease, or even wrong (over-) diagnosis.

As found in previous studies, one of the main limitations of register studies in general is the opposite, i.e. not being able to identify either chronic patients who have not been treated or diagnosed at any time or patients with self-treated conditions, who consequently are not reported in hospital or other registers (i.e. data source limitations, etc.) \[[@CR44], [@CR55]\]. This may lead to under-reporting of some less severe chronic conditions, such as asthma, allergies, COPD and type 2 diabetes, which are mostly treated in primary care where there is no reporting of diagnoses. The same might apply for other conditions such as glaucoma, cataracts, age-related hearing loss, other eye and ear conditions, and less severe mental conditions that are untreated, such as mild forms of depression or anxiety \[[@CR44]\]. Thus, differences in the present study are compared with the national self-reported prevalence rates for 2013 for 18 broadly defined conditions where possible, since they cover a wide range of conditions of importance for assessment \[[@CR6]\]. In comparison, differences and limitations of register-based definitions might be found within four of the 18 conditions: osteoarthritis, migraine/headache, tinnitus and cataracts. These conditions are discussed in more detail in Supplementary Material 3. All in all, these register-based less severe conditions may not be sufficiently estimated at this time, which is why register-based prevalence will be underestimated and should be used with caution.

While some estimated conditions show limitations compared to self-reported conditions, most other conditions, such as hypertension, rheumatoid arthritis, osteoporosis, diabetes, COPD, bronchitis and other lung diseases, cancers, heart condition and stroke, all have higher or slightly higher register-based than self-reported prevalence \[[@CR6]\], as well as estimates in line with other studies \[[@CR7], [@CR10], [@CR33], [@CR55], [@CR56]\]. The same applies to mental conditions overall, which typically have a lower survey response \[[@CR57]\], which could explain the lower self-reported prevalence. Added to the fact that these estimates are free of self-reported bias, this clearly strengthens the reliability of most register-based conditions reported, not to mention the enhanced precision of doctor-reported diagnoses.

However, similar to non-registration issues in community-based surveys, misclassification issues also exist in register studies as sources of bias. Reasons for this include different coding practices between hospitals \[[@CR30]\], different access to specialists, clinical disagreements, different clinical and administrative practices and interpretation of the ICD-10 criteria \[[@CR58]\]. However, we do not have evidence of systemic misclassification. On the contrary, studies have validated reported diagnoses from registers for several psychiatric and somatic conditions, with good overall results \[[@CR55], [@CR59]--[@CR64]\]. Nevertheless, the estimates of some complex-aetiology, ill-defined and debated rheumatoid conditions such as fibromyalgia and chronic fatigue syndrome, even though common, should be used with caution since they are clearly under-reported compared to other studies \[[@CR58], [@CR65], [@CR66]\]. Further discussion and references regarding the validity of diagnosis codes in registers can be found elsewhere \[[@CR44]\].

In summary, the prevalence of some less severe conditions may be underestimated in register studies \[[@CR55]\]. On the other hand, community-based self-reported studies may underestimate, especially, the more severe conditions due to, among other things, non-responders as well as people living in institutions or jails, homeless people, and those currently in inpatient treatment. Existing studies have already shown varying or poor overlap between self-reports and hospital reports \[[@CR67]\], some concluding that the use of self-reports is less reliable in cases of, for example, stroke and ischaemic heart disease \[[@CR68], [@CR69]\], while severe conditions \[[@CR67]\] such as cancers cannot reliably be self-diagnosed. Thus, a strength of the current study is that moderate or severe conditions are estimated more accurately and are naturally free of the bias of self-reported conditions. From this perspective, community-based survey studies contrast with and complement register studies \[[@CR55]\].

Another strength of the study is that the definitions used were evaluated by epidemiologists and clinicians to strengthen reliability and provide the best possible representation \[[@CR44]\]. In addition, the long register time periods are noticeable strengths compared to other register studies \[[@CR7], [@CR24], [@CR26], [@CR29]--[@CR31]\]. Lastly, the use of a complete population of 4,555,439 people, not to mention the large number of ICD-10 doctor-reported conditions included, is another strength not or rarely seen in other studies.

Implications {#Sec12}
------------

Existing international register studies usually help determine current disease burden with implications for, for example, the funding of new treatments or others---but usually not multiple conditions \[[@CR70]--[@CR72]\].

The prevalence estimates of the current study provide unbiased, independent important basic information regarding the burden of disease for use in healthcare planning, as well as economic, aetiological and other research for a broad range of conditions. As it is based on uniform methodology within a single study, it also makes reliable comparisons, contrary to most existing studies. In many types of health economic studies, such as analyses of cost of illness and the budgetary consequences of the introduction of new health technologies, economic calculations may not provide an accurate, reliable picture if based on invalid information. This comprehensive catalogue of prevalence information of nationwide chronic conditions enables comprehensive comparisons of chronic diseases for policymakers, patient associations and researchers. Thus, it may serve as an off-the-shelf tool for decision makers and researchers for health economic modelling.

Future Studies {#Sec13}
--------------

The World Health Organization (WHO) have recommended further improvement in data surveillance of chronic conditions worldwide \[[@CR17]\]; in addition, other studies have criticised, as well as recommended, methodological improvements \[[@CR73]--[@CR76]\]. Future studies should compare these prevalence rates based on actual patient pathways and registrations of treatment with other methods for estimating disease prevalence. Future studies could also focus on the development over time of disease burden, including the newest register data and analysis of possible trends in diagnosis or possible over-diagnosis. Moreover, while there are several studies exploring the coherence between self-reported conditions and hospital records, we found no studies assessing whether less severe self-reported conditions are more accurately estimated than register-reported conditions. Further studies should be carried out to assess whether chosen less severe self-reported conditions are estimated accurately, and if so, how register and self-reported study designs could best complement each other and for which conditions.

Conclusions {#Sec14}
===========

The current study provides a catalogue of prevalence for 199 different doctor-reported chronic conditions and groups of conditions by gender, based on a complete nationwide population sample.

To the best of the authors' knowledge, this study provides the most comprehensive descriptive register study of the prevalence of treatment of chronic conditions. Hence, the overall prevalence rate found is higher than that found in several previous studies, indicating that almost two-thirds of the entire Danish population aged 16 years or above either have a hospital diagnosis and/or are in medical treatment for one or more chronic condition.

Electronic supplementary material
=================================

 {#Sec15}

Below is the link to the electronic supplementary material. Supplementary material 1 (PDF 2267 kb)
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